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BACKGROUND
As of 2014, the modern contraceptive prevalence rate
in Ghana was 22 percent (2014 Ghana Demographic
& Health Survey) and the total fertility rate was 4.2.
The injectable is the most popular modern contraceptive method used by married women in the country,
accounting for 36 percent of modern method use
(2014 Ghana Demographic & Health Survey).
Sayana® Press is a three-month, progestin-only,
all-in-one injectable contraceptive that combines the
drug and needle in the Uniject injection system (PATH,
2016). Due to its Uniject method, Sayana® Press is
small, light, easy-to-use, requires minimal training and
is expected to help in improving provision of family
planning services in low-resource settings (PATH,
2016). Sayana® Press could be particularly useful in
Ghana where access to family planning services is curtailed by the distance to clinics, for example. Sayana®

ACTIVIT Y DESIGN
GHS and the Evidence Project formed a multi-sectoral
technical advisory group (TAG) comprised of stakeholders from GHS, USAID/Ghana, UNFPA, PSI, SHOPS,
Planned Parenthood Association of Ghana, Health
Keepers Network, and DKT International. TAG members were actively engaged in discussions and decisions around the design of the study protocol and have
participated in meetings on study results.
Pfizer, Inc. registered Sayana® Press in-country,
allowing for the commodity to be procured by UNFPA
on behalf of GHS. Eight resource persons, four from
each study region, attended a four-day training with a
master trainer from PATH/Uganda to become Ghana
master trainers. Master trainers trained health pro-

Press is suitable for community-based distribution and
for women to administer themselves through self-injection. Through self-injection, Sayana® Press can
improve access to a safe and effective contraceptive
option and increase women’s autonomy.
At the request of the Ghana Health Service (GHS), the
Evidence Project, through the Population Council and
with funding from USAID/Ghana, is studying the feasibility and acceptability of Sayana® Press self-injection,
and by extension, informing its introduction in Ghana.
The primary objectives of the seven-month study are
to assess the feasibility of introducing Sayana® Press
self-injection and its acceptability among both health
workers and injectable clients. Results from the study
are expected to inform the national strategy, including
procurement and scale-up of Sayana® Press in the
public and private sectors.

viders across eight public health facilities selected as
study sites by the TAG in the Ashanti and Volta regions.
One hundred and fifty providers (71 in Ashanti region
and 79 in Volta region) completed a questionnaire
both before and after receiving three days of training
on Sayana® Press counseling, administration and
client self-injection, which included practicing injections on non-human models. Eighty-eight percent of
providers are women and sixty-five percent are community health nurses, the rest being midwives, community
health officers, enrolled nurses or other. The master
trainers followed up with supportive supervision visits
to each facility, where the providers were assessed on
simulating how to teach a client to self-inject using a
self-injection practice checklist.
Thirty-two data collectors (16 per region) were trained
in November 2017 over a three-day period on the principles of research (ethical conduct), research methodology, and study instruments. They also role-played to
practice interviewing clients. Data collection began in
December 2017.
At each injection, clients chose provider-administered
injection or to be trained by the provider to self-inject.
Clients who demonstrated self-injection competence
were given up to two Sayana® Press packs to take
home to self-inject. Clients who agreed to participate
in the seven-month study were interviewed after each
injection (a total of three). The first round of interviews
was conducted from the first week of December 2017 to
the last week of January 2018, where a total of 589 clients were recruited into the study. The second round is
from the first week of March to the second week in May.
To monitor service delivery of Sayana® Press, special
provisions have been made to include the commodity
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into the GHS Reproductive Service Log (rsLog), an
electronic platform to capture family planning services
in public health facilities. These data are beneficial in
assessing uptake, continuity and discontinuity beyond
the study period.
An early analysis of the client data indicates that this
study may also yield interesting findings on clients’
progression to self-injection, a unique feature of this
study’s design as compared to Sayana® Press feasibility and acceptability studies conducted elsewhere
in sub-Saharan Africa. As of Round 1, 36 percent of all
study clients self-injected Sayana® Press.
The Ghana Health Service has a strong commitment
to task shifting to accelerate access to modern contraceptive methods. GHS’s commitment to engaging all
relevant stakeholders in the public, private and NGOs
sectors in the study process provides an excellent
model for maximizing research utilization.
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